EU and US could reach trade deal this weekend - Reuters
CAMBRIDGE, Mass. - Seres Therapeutics, Inc. (NASDAQ:MCRB), a biopharmaceutical company specializing in live biotherapeutics with a current market capitalization of $67 million, announced today that it will present new biomarker data from its SER-155 Phase 1b study at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The event is scheduled to take place from May 30 to June 3 in Chicago. According to InvestingPro analysis, the company maintains a healthy current ratio of 2.11, indicating strong short-term liquidity despite recent market challenges.
The data to be presented builds upon previous findings from the SER-155 Phase 1b study, which indicated improved intestinal barrier integrity and modulation of systemic inflammatory responses. These results were consistent with SER-155’s intended therapeutic mechanisms, which aim to reduce the risk of infections related to intestinal bacterial translocation and have shown a significant reduction in bloodstream infections (BSIs) by 77% relative to placebo. While the clinical results appear promising, InvestingPro data reveals the company is currently rated ’Weak’ in overall financial health, with a score of 1.7 out of 5, reflecting the challenges typical of pre-commercial biotech companies.
The new biomarker data focuses on SER-155’s potential to promote immune reconstitution following allogeneic hematopoietic stem cell transplantation (allo-HSCT) through the modulation of homeostatic cytokines and T-cell expansion. Significant increases in the homeostatic cytokine IL-7 and frequencies of CD4+ T cells were observed in the SER-155 treatment group, suggesting a role in promoting T-cell populations essential for immune reconstitution after allo-HSCT.
Dr. Marcel van den Brink, President of City of Hope Cancer Center, highlighted the importance of restoring a diverse, functional T-cell population post-transplantation to improve clinical outcomes. The findings suggest that SER-155 may support more robust and functional immune recovery and, combined with the reduction in bloodstream infections, warrant continued clinical development.
Seres Therapeutics plans to submit a Phase 2 trial protocol for SER-155 to the FDA in the coming weeks and is actively seeking partnerships for further clinical development. SER-155 has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing infection and graft-versus-host disease risks in this patient population.
The company’s research into SER-155 and other live biotherapeutic candidates aims to address various medical conditions in vulnerable patient populations, including those undergoing different types of transplants and intensive care treatments. This announcement is based on a press release statement from Seres Therapeutics, Inc. With a high beta of 2.88 and a significant six-month decline of 58% in share price, investors seeking detailed analysis can access comprehensive financial metrics and 10+ additional ProTips through InvestingPro’s exclusive research reports.
In other recent news, Seres Therapeutics has reported a significant improvement in its financial performance for the first quarter of 2025, achieving a net income of $32.7 million compared to a net loss of $32.9 million in the same period last year. This turnaround was largely driven by a $50 million installment payment from Nestlé. The company’s cash and cash equivalents increased to $58.8 million, up from $30.8 million at the end of the previous fiscal year. Despite these positive financial results, Chardan Capital Markets downgraded Seres Therapeutics’ stock rating from Buy to Neutral, setting a price target of $6.00. This decision reflects the company’s need for a partnership to fund the advancement of its drug candidate, SER-155, into Phase II studies. Seres Therapeutics is currently in discussions with the FDA about the development of SER-155 for allo-HSCT, with plans to submit a Phase II protocol in the coming weeks. The FDA has recommended a Phase II standalone trial, which aims to enroll approximately 248 participants to focus on preventing bloodstream infections. The company anticipates an interim analysis once half of the participants reach their primary endpoint, potentially influencing future clinical trial designs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.